NEWTON, MA – Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a pharmaceutical company specializing in the development of novel cancer therapies, announced today the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer, and Treasurer, effective Friday.
This transition follows a December 12, 2024, board decision and is part of the company's ongoing leadership restructuring.
Ms. Macomber, 54, brings a wealth of experience to Karyopharm, having previously held the CFO position at Legend Biotech Corporation until her recent move. Her career spans various financial leadership roles in notable companies, including Ametek (NYSE:AME) PDS and Cello Health, as well as significant stints at Eli Lily and Pfizer Inc. (NYSE:PFE)
In her new role, Macomber will receive an annual base salary of $475,000 and is eligible for a performance-based annual bonus targeting 45% of her base salary. Additionally, as part of her compensation, she has been granted an inducement award consisting of a stock option to purchase 650,000 shares and 160,000 restricted stock units under the company's 2022 Inducement Stock Incentive Plan. These awards are subject to vesting over a period of time, contingent on her continued service.
Kristin Abate, who served as the interim principal financial officer, will step down from this interim role concurrent with Macomber's appointment.
The news above is based on an SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.